NO300461B1 - 2,6-Disubstituerte purinderivater - Google Patents
2,6-Disubstituerte purinderivater Download PDFInfo
- Publication number
- NO300461B1 NO300461B1 NO941477A NO941477A NO300461B1 NO 300461 B1 NO300461 B1 NO 300461B1 NO 941477 A NO941477 A NO 941477A NO 941477 A NO941477 A NO 941477A NO 300461 B1 NO300461 B1 NO 300461B1
- Authority
- NO
- Norway
- Prior art keywords
- adenosine
- chloro
- mmol
- piperidinyl
- phenyl
- Prior art date
Links
- -1 2,6-Disubstituted Purine Chemical class 0.000 title claims description 21
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 74
- 229910052739 hydrogen Inorganic materials 0.000 claims description 65
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 36
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 19
- 229960005305 adenosine Drugs 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 14
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 10
- LONOTIOGPDFYIZ-WVSUBDOOSA-N (2r,3r,4s,5r)-2-[2-chloro-6-[(4-phenylsulfanylpiperidin-1-yl)amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(Cl)=NC(NN3CCC(CC3)SC=3C=CC=CC=3)=C2N=C1 LONOTIOGPDFYIZ-WVSUBDOOSA-N 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 208000015114 central nervous system disease Diseases 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- JDCGTCRTLUOWTP-IDTAVKCVSA-N (2r,3r,4s,5r)-2-[2-chloro-6-(piperidin-1-ylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(Cl)=NC(NN3CCCCC3)=C2N=C1 JDCGTCRTLUOWTP-IDTAVKCVSA-N 0.000 claims description 3
- RFBNBCYROPRGHW-UEXBNONGSA-N (2r,3r,4s,5r)-2-[2-chloro-6-[(3-phenoxypiperidin-1-yl)amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(Cl)=NC(NN3CC(CCC3)OC=3C=CC=CC=3)=C2N=C1 RFBNBCYROPRGHW-UEXBNONGSA-N 0.000 claims description 3
- YCOZBWPHZVRWMM-NVQRDWNXSA-N (2r,3r,4s,5r)-2-[2-chloro-6-[(4-phenylpiperazin-1-yl)amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(Cl)=NC(NN3CCN(CC3)C=3C=CC=CC=3)=C2N=C1 YCOZBWPHZVRWMM-NVQRDWNXSA-N 0.000 claims description 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- YIBZLEUFUQPPBJ-WVSUBDOOSA-N (2r,3r,4s,5r)-2-[2-chloro-6-[(4-phenoxypiperidin-1-yl)amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(Cl)=NC(NN3CCC(CC3)OC=3C=CC=CC=3)=C2N=C1 YIBZLEUFUQPPBJ-WVSUBDOOSA-N 0.000 claims description 2
- LAOQQTUMHSUVFJ-IDTAVKCVSA-N (2r,3r,4s,5r)-2-[2-fluoro-6-(piperidin-1-ylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(F)=NC(NN3CCCCC3)=C2N=C1 LAOQQTUMHSUVFJ-IDTAVKCVSA-N 0.000 claims description 2
- YFHYXENKDUPFSL-WVSUBDOOSA-N (2r,3r,4s,5r)-2-[6-[[4-(benzenesulfonyl)piperidin-1-yl]amino]-2-chloropurin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(Cl)=NC(NN3CCC(CC3)S(=O)(=O)C=3C=CC=CC=3)=C2N=C1 YFHYXENKDUPFSL-WVSUBDOOSA-N 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 90
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 66
- 238000000034 method Methods 0.000 description 41
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- 239000000243 solution Substances 0.000 description 28
- 239000006260 foam Substances 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 239000011541 reaction mixture Substances 0.000 description 20
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- 238000010828 elution Methods 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000004440 column chromatography Methods 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 230000014759 maintenance of location Effects 0.000 description 10
- 239000003379 purinergic P1 receptor agonist Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 238000007360 debenzoylation reaction Methods 0.000 description 9
- 239000012264 purified product Substances 0.000 description 9
- 238000004809 thin layer chromatography Methods 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 210000003169 central nervous system Anatomy 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 7
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 7
- 235000011130 ammonium sulphate Nutrition 0.000 description 7
- 238000003818 flash chromatography Methods 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 6
- 229910004298 SiO 2 Inorganic materials 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- GADIKQPUNWAMEB-UHFFFAOYSA-N methyl 4-ethyl-6,7-dimethoxy-9H-pyrido[5,4-b]indole-3-carboxylate Chemical compound N1C2=CC(OC)=C(OC)C=C2C2=C1C=NC(C(=O)OC)=C2CC GADIKQPUNWAMEB-UHFFFAOYSA-N 0.000 description 6
- 230000004770 neurodegeneration Effects 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 108050000203 Adenosine receptors Proteins 0.000 description 5
- 102000009346 Adenosine receptors Human genes 0.000 description 5
- 206010053398 Clonic convulsion Diseases 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 150000002431 hydrogen Chemical class 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 208000028867 ischemia Diseases 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 239000002777 nucleoside Substances 0.000 description 5
- 229940122614 Adenosine receptor agonist Drugs 0.000 description 4
- 206010002660 Anoxia Diseases 0.000 description 4
- 241000976983 Anoxia Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 150000003838 adenosines Chemical class 0.000 description 4
- 230000007953 anoxia Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 description 4
- LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical compound NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 150000003835 adenosine derivatives Chemical class 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 239000008259 solid foam Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- UIJXHKXIOCDSEB-UHFFFAOYSA-N tert-butyl 3-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(O)C1 UIJXHKXIOCDSEB-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- JKQATMIEYXFKHM-HVMNINKTSA-N (2r,3r,4s,5r)-2-[2-chloro-6-[(3-hydroxypiperidin-1-yl)amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(Cl)=NC(NN3CC(O)CCC3)=C2N=C1 JKQATMIEYXFKHM-HVMNINKTSA-N 0.000 description 2
- ZSCYGLKOOQLWEJ-UEXBNONGSA-N (2r,3r,4s,5r)-2-[2-chloro-6-[(3-phenylsulfanylpiperidin-1-yl)amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(Cl)=NC(NN3CC(CCC3)SC=3C=CC=CC=3)=C2N=C1 ZSCYGLKOOQLWEJ-UEXBNONGSA-N 0.000 description 2
- JNNYZBNVSXWLMB-WVSUBDOOSA-N (2r,3r,4s,5r)-2-[2-chloro-6-[(4-phenyl-3,6-dihydro-2h-pyridin-1-yl)amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(Cl)=NC(NN3CC=C(CC3)C=3C=CC=CC=3)=C2N=C1 JNNYZBNVSXWLMB-WVSUBDOOSA-N 0.000 description 2
- YOEXNQZGJPAMKT-WVSUBDOOSA-N (2r,3r,4s,5r)-2-[2-chloro-6-[(4-phenylpiperidin-1-yl)amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(Cl)=NC(NN3CCC(CC3)C=3C=CC=CC=3)=C2N=C1 YOEXNQZGJPAMKT-WVSUBDOOSA-N 0.000 description 2
- VMOZLWKIEHKCGN-SDBHATRESA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[2-methylsulfanyl-6-(piperidin-1-ylamino)purin-9-yl]oxolane-3,4-diol Chemical compound C=12N=CN([C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C2=NC(SC)=NC=1NN1CCCCC1 VMOZLWKIEHKCGN-SDBHATRESA-N 0.000 description 2
- QDPNIJKUTWDGMV-UHFFFAOYSA-N 3-phenoxypiperidine Chemical compound C1CCNCC1OC1=CC=CC=C1 QDPNIJKUTWDGMV-UHFFFAOYSA-N 0.000 description 2
- 101150007969 ADORA1 gene Proteins 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical class NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 108010060263 Adenosine A1 Receptor Proteins 0.000 description 2
- 102000030814 Adenosine A1 receptor Human genes 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 2
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 2
- 102000004300 GABA-A Receptors Human genes 0.000 description 2
- 108090000839 GABA-A Receptors Proteins 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010043994 Tonic convulsion Diseases 0.000 description 2
- AYLIMCLJJXIMLT-WVSUBDOOSA-N [(2r,3r,4r,5r)-3,4-diacetyloxy-5-[2-bromo-6-(piperidin-1-ylamino)purin-9-yl]oxolan-2-yl]methyl acetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@H]1N1C2=NC(Br)=NC(NN3CCCCC3)=C2N=C1 AYLIMCLJJXIMLT-WVSUBDOOSA-N 0.000 description 2
- ANHPGXFOKHHDCK-DWCTZGTLSA-N [(2r,3r,4r,5r)-3,4-dibenzoyloxy-5-[2-chloro-6-(piperidin-1-ylamino)purin-9-yl]oxolan-2-yl]methyl benzoate Chemical compound C=12N=CN([C@H]3[C@@H]([C@H](OC(=O)C=4C=CC=CC=4)[C@@H](COC(=O)C=4C=CC=CC=4)O3)OC(=O)C=3C=CC=CC=3)C2=NC(Cl)=NC=1NN1CCCCC1 ANHPGXFOKHHDCK-DWCTZGTLSA-N 0.000 description 2
- RTRQQBHATOEIAF-UUOKFMHZSA-N acadesine Chemical compound NC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RTRQQBHATOEIAF-UUOKFMHZSA-N 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- DIKBFYAXUHHXCS-UHFFFAOYSA-N bromoform Chemical compound BrC(Br)Br DIKBFYAXUHHXCS-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 230000002566 clonic effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- WQOXQRCZOLPYPM-UHFFFAOYSA-N dimethyl disulfide Chemical compound CSSC WQOXQRCZOLPYPM-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- KTVYGDJRKCXTRA-UHFFFAOYSA-N hydron;pyrrolidin-1-amine;chloride Chemical compound Cl.NN1CCCC1 KTVYGDJRKCXTRA-UHFFFAOYSA-N 0.000 description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000004090 neuroprotective agent Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BIWOSRSKDCZIFM-UHFFFAOYSA-N piperidin-3-ol Chemical compound OC1CCCNC1 BIWOSRSKDCZIFM-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- RIRGCFBBHQEQQH-SSFGXONLSA-N (-)-n6-(2-phenylisopropyl)adenosine Chemical compound C([C@@H](C)NC=1C=2N=CN(C=2N=CN=1)[C@H]1[C@@H]([C@H](O)[C@@H](CO)O1)O)C1=CC=CC=C1 RIRGCFBBHQEQQH-SSFGXONLSA-N 0.000 description 1
- REEFXARZCXCDCA-UUOKFMHZSA-N (2r,3r,4s,5r)-2-(2-amino-6-hydrazinylpurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(NN)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O REEFXARZCXCDCA-UUOKFMHZSA-N 0.000 description 1
- LUJRYEHLJHMAFN-UUOKFMHZSA-N (2r,3r,4s,5r)-2-(2-fluoro-6-hydrazinylpurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(NN)=NC(F)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O LUJRYEHLJHMAFN-UUOKFMHZSA-N 0.000 description 1
- DGKZTAGCCXJUAT-KQYNXXCUSA-N (2r,3r,4s,5r)-2-(6-hydrazinylpurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(NN)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O DGKZTAGCCXJUAT-KQYNXXCUSA-N 0.000 description 1
- TUZPRGFGHIAOII-IDTAVKCVSA-N (2r,3r,4s,5r)-2-[2-amino-6-(piperidin-1-ylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=12N=CN([C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C2=NC(N)=NC=1NN1CCCCC1 TUZPRGFGHIAOII-IDTAVKCVSA-N 0.000 description 1
- WXOHKINLTMKOIK-IDTAVKCVSA-N (2r,3r,4s,5r)-2-[2-bromo-6-(piperidin-1-ylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(Br)=NC(NN3CCCCC3)=C2N=C1 WXOHKINLTMKOIK-IDTAVKCVSA-N 0.000 description 1
- SNTVGVURAAEEMQ-QYVSTXNMSA-N (2r,3r,4s,5r)-2-[2-chloro-6-(morpholin-4-ylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(Cl)=NC(NN3CCOCC3)=C2N=C1 SNTVGVURAAEEMQ-QYVSTXNMSA-N 0.000 description 1
- ILZHIIYOBNNOFS-FDEMZPBOSA-N (2r,3r,4s,5r)-2-[2-chloro-6-[(2,6-dimethylpiperidin-1-yl)amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound CC1CCCC(C)N1NC1=NC(Cl)=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ILZHIIYOBNNOFS-FDEMZPBOSA-N 0.000 description 1
- BMGCRYRNEQUYDH-UEXBNONGSA-N (2r,3r,4s,5r)-2-[2-chloro-6-[(2-phenylpiperidin-1-yl)amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(Cl)=NC(NN3C(CCCC3)C=3C=CC=CC=3)=C2N=C1 BMGCRYRNEQUYDH-UEXBNONGSA-N 0.000 description 1
- BFXKBPPVQQSRSA-IDTAVKCVSA-N (2r,3r,4s,5r)-2-[2-chloro-6-[(4-methylpiperazin-1-yl)amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1CN(C)CCN1NC1=NC(Cl)=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 BFXKBPPVQQSRSA-IDTAVKCVSA-N 0.000 description 1
- XTLNQUUIHXVPAT-OHYWOBESSA-N (2r,3r,4s,5r)-2-[2-chloro-6-[[2-(phenylsulfanylmethyl)piperidin-1-yl]amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(Cl)=NC(NN3C(CCCC3)CSC=3C=CC=CC=3)=C2N=C1 XTLNQUUIHXVPAT-OHYWOBESSA-N 0.000 description 1
- HBYSXODERFBLJU-KQYNXXCUSA-N (2r,3r,4s,5r)-2-[2-fluoro-6-(methoxyamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(NOC)=NC(F)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HBYSXODERFBLJU-KQYNXXCUSA-N 0.000 description 1
- VWSMQPRPOXQJRH-QYVSTXNMSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[2-iodo-6-(pyrrolidin-1-ylamino)purin-9-yl]oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(I)=NC(NN3CCCC3)=C2N=C1 VWSMQPRPOXQJRH-QYVSTXNMSA-N 0.000 description 1
- ORBBAWPEINOUJR-IOSLPCCCSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-(2-methylhydrazinyl)purin-9-yl]oxolane-3,4-diol Chemical compound C1=NC=2C(NNC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ORBBAWPEINOUJR-IOSLPCCCSA-N 0.000 description 1
- YCBXJRXEANYVPH-LSCFUAHRSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-(piperidin-1-ylamino)-2-propoxypurin-9-yl]oxolane-3,4-diol Chemical compound C=12N=CN([C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C2=NC(OCCC)=NC=1NN1CCCCC1 YCBXJRXEANYVPH-LSCFUAHRSA-N 0.000 description 1
- HEZVCCWYHSHJPF-UHFFFAOYSA-N 1-aminopiperidin-3-ol Chemical compound NN1CCCC(O)C1 HEZVCCWYHSHJPF-UHFFFAOYSA-N 0.000 description 1
- RMFWVOLULURGJI-UHFFFAOYSA-N 2,6-dichloro-7h-purine Chemical compound ClC1=NC(Cl)=C2NC=NC2=N1 RMFWVOLULURGJI-UHFFFAOYSA-N 0.000 description 1
- HXRZJBGIGABYSY-UHFFFAOYSA-N 2-(phenylsulfanylmethyl)piperidin-1-amine Chemical compound NN1CCCCC1CSC1=CC=CC=C1 HXRZJBGIGABYSY-UHFFFAOYSA-N 0.000 description 1
- NUZVSWGFCLEVIL-UHFFFAOYSA-N 2-(phenylsulfanylmethyl)piperidine Chemical compound C1CCCNC1CSC1=CC=CC=C1 NUZVSWGFCLEVIL-UHFFFAOYSA-N 0.000 description 1
- ZDTFMPXQUSBYRL-UUOKFMHZSA-N 2-Aminoadenosine Chemical class C12=NC(N)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ZDTFMPXQUSBYRL-UUOKFMHZSA-N 0.000 description 1
- RILZRCJGXSFXNE-UHFFFAOYSA-N 2-[4-(trifluoromethoxy)phenyl]ethanol Chemical compound OCCC1=CC=C(OC(F)(F)F)C=C1 RILZRCJGXSFXNE-UHFFFAOYSA-N 0.000 description 1
- XQDSIGDVDWFZPP-UHFFFAOYSA-N 2-phenylpiperidin-1-amine Chemical compound NN1CCCCC1C1=CC=CC=C1 XQDSIGDVDWFZPP-UHFFFAOYSA-N 0.000 description 1
- JUHGSJAEOSAICF-UHFFFAOYSA-N 3-phenoxypiperidin-1-amine Chemical compound C1N(N)CCCC1OC1=CC=CC=C1 JUHGSJAEOSAICF-UHFFFAOYSA-N 0.000 description 1
- DSLRUORCIMJTAW-UHFFFAOYSA-N 3-phenylsulfanylpiperidin-1-amine Chemical compound C1N(N)CCCC1SC1=CC=CC=C1 DSLRUORCIMJTAW-UHFFFAOYSA-N 0.000 description 1
- MIRYNHKEQYZFKF-UHFFFAOYSA-N 3-phenylsulfanylpiperidine Chemical compound C1CCNCC1SC1=CC=CC=C1 MIRYNHKEQYZFKF-UHFFFAOYSA-N 0.000 description 1
- OYQPUKKJNBVCPI-UHFFFAOYSA-N 4-phenoxypiperidin-1-amine Chemical compound C1CN(N)CCC1OC1=CC=CC=C1 OYQPUKKJNBVCPI-UHFFFAOYSA-N 0.000 description 1
- WLCHHTKJBLNKAU-UHFFFAOYSA-N 4-phenyl-3,6-dihydro-2h-pyridin-1-amine Chemical compound C1N(N)CCC(C=2C=CC=CC=2)=C1 WLCHHTKJBLNKAU-UHFFFAOYSA-N 0.000 description 1
- LYMDNMCPLFABAM-UHFFFAOYSA-N 4-phenylpiperazin-1-amine;hydrochloride Chemical compound Cl.C1CN(N)CCN1C1=CC=CC=C1 LYMDNMCPLFABAM-UHFFFAOYSA-N 0.000 description 1
- XIKMXKPROKIFSY-UHFFFAOYSA-N 4-phenylpiperidin-1-amine Chemical compound C1CN(N)CCC1C1=CC=CC=C1 XIKMXKPROKIFSY-UHFFFAOYSA-N 0.000 description 1
- CYPMHULHKAKVMW-UHFFFAOYSA-N 4-phenylsulfanylpiperidin-1-amine Chemical compound C1CN(N)CCC1SC1=CC=CC=C1 CYPMHULHKAKVMW-UHFFFAOYSA-N 0.000 description 1
- RTRQQBHATOEIAF-UHFFFAOYSA-N AICA riboside Natural products NC1=C(C(=O)N)N=CN1C1C(O)C(O)C(CO)O1 RTRQQBHATOEIAF-UHFFFAOYSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000593806 Phyllis Species 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- GCZABPLTDYVJMP-ASAMFVBJSA-N [(2r,3r,4r)-5-acetyloxy-3,4-dibenzoyloxyoxolan-2-yl]methyl benzoate Chemical compound C([C@H]1OC([C@@H]([C@@H]1OC(=O)C=1C=CC=CC=1)OC(=O)C=1C=CC=CC=1)OC(=O)C)OC(=O)C1=CC=CC=C1 GCZABPLTDYVJMP-ASAMFVBJSA-N 0.000 description 1
- HTAVPUVJRBFRIM-WVSUBDOOSA-N [(2r,3r,4r,5r)-3,4-diacetyloxy-5-[2-amino-6-(piperidin-1-ylamino)purin-9-yl]oxolan-2-yl]methyl acetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@H]1N1C2=NC(N)=NC(NN3CCCCC3)=C2N=C1 HTAVPUVJRBFRIM-WVSUBDOOSA-N 0.000 description 1
- FXCFWEYKMUWIBA-WVSUBDOOSA-N [(2r,3r,4r,5r)-3,4-diacetyloxy-5-[2-fluoro-6-(piperidin-1-ylamino)purin-9-yl]oxolan-2-yl]methyl acetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@H]1N1C2=NC(F)=NC(NN3CCCCC3)=C2N=C1 FXCFWEYKMUWIBA-WVSUBDOOSA-N 0.000 description 1
- FCKDJIJLBNKKGF-QTQZEZTPSA-N [(2r,3r,4r,5r)-3,4-diacetyloxy-5-[6-(piperidin-1-ylamino)purin-9-yl]oxolan-2-yl]methyl acetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@H]1N1C2=NC=NC(NN3CCCCC3)=C2N=C1 FCKDJIJLBNKKGF-QTQZEZTPSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 229940121359 adenosine receptor antagonist Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 229940125682 antidementia agent Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 229950005228 bromoform Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001966 cerebroprotective effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- FPUGCISOLXNPPC-IOSLPCCCSA-N cordysinin B Chemical class CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2N=C1 FPUGCISOLXNPPC-IOSLPCCCSA-N 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical class OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- MKQLBNJQQZRQJU-UHFFFAOYSA-N morpholin-4-amine Chemical compound NN1CCOCC1 MKQLBNJQQZRQJU-UHFFFAOYSA-N 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940059574 pentaerithrityl Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- PRAYXGYYVXRDDW-UHFFFAOYSA-N piperidin-2-ylmethanol Chemical compound OCC1CCCCN1 PRAYXGYYVXRDDW-UHFFFAOYSA-N 0.000 description 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- HDMGAZBPFLDBCX-UHFFFAOYSA-M potassium;sulfooxy sulfate Chemical compound [K+].OS(=O)(=O)OOS([O-])(=O)=O HDMGAZBPFLDBCX-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 description 1
- 239000003422 purinergic receptor affecting agent Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK9100324 | 1991-10-24 | ||
| PCT/DK1992/000307 WO1993008206A1 (fr) | 1991-10-24 | 1992-10-21 | Nouveaux derives de purine 2,6-disubstitues |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO941477D0 NO941477D0 (no) | 1994-04-22 |
| NO941477L NO941477L (fr) | 1994-06-23 |
| NO300461B1 true NO300461B1 (no) | 1997-06-02 |
Family
ID=8153695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO941477A NO300461B1 (no) | 1991-10-24 | 1994-04-22 | 2,6-Disubstituerte purinderivater |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US5432164A (fr) |
| EP (1) | EP0609375A1 (fr) |
| JP (1) | JPH07500586A (fr) |
| AU (1) | AU657374B2 (fr) |
| CA (1) | CA2121844A1 (fr) |
| FI (1) | FI941876A (fr) |
| IL (1) | IL103513A (fr) |
| NO (1) | NO300461B1 (fr) |
| NZ (1) | NZ244875A (fr) |
| WO (1) | WO1993008206A1 (fr) |
| ZA (1) | ZA928222B (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5432164A (en) * | 1991-10-24 | 1995-07-11 | Novo Nordisk A/S | C2,N6 -disubstituted adenosine derivatives |
| US5589467A (en) * | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
| EP0704215A3 (fr) * | 1994-06-02 | 1998-04-01 | Takeda Chemical Industries, Ltd. | Inhibiteur de l'aumentation de la perméabilité vasculaire |
| WO1997033591A1 (fr) * | 1996-03-13 | 1997-09-18 | Novo Nordisk A/S | Procede de traitement d'affections associees aux cytokines chez les mammiferes |
| AU2022497A (en) * | 1996-03-13 | 1997-10-01 | Novo Nordisk A/S | A method of treating disorders related to cytokines in mammals |
| US5789416B1 (en) * | 1996-08-27 | 1999-10-05 | Cv Therapeutics Inc | N6 mono heterocyclic substituted adenosine derivatives |
| AU4377397A (en) * | 1996-10-14 | 1998-05-11 | Novo Nordisk A/S | Novel therapeutically active adenosine derivatives |
| US6110902A (en) * | 1997-06-23 | 2000-08-29 | Moehler; Hanns | Method for the inhibition of neuronal activity leading to a focal epileptic seizure by local delivery of adenosine |
| US6175004B1 (en) * | 1998-09-01 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Process for the synthesis of oligonucleotides incorporating 2-aminoadenosine |
| US6576619B2 (en) | 1999-05-24 | 2003-06-10 | Cv Therapeutics, Inc. | Orally active A1 adenosine receptor agonists |
| US6294522B1 (en) * | 1999-12-03 | 2001-09-25 | Cv Therapeutics, Inc. | N6 heterocyclic 8-modified adenosine derivatives |
| US7342003B2 (en) * | 2001-10-25 | 2008-03-11 | King Pharmaceuticals Research And Development, Inc. | Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs |
| CA2515068A1 (fr) * | 2003-02-03 | 2004-08-19 | Cv Therapeutics Inc. | Agonistes partiels et pleins des recepteurs a<sb>1</sb> de l'adenosine |
| WO2005033121A2 (fr) * | 2003-10-03 | 2005-04-14 | King Pharmaceuticals Research & Development, Inc. | Synthese de 2-aralkyloxyadenosines, 2-alkoxyadenosines, et leurs analogues |
| WO2007107598A1 (fr) | 2006-03-21 | 2007-09-27 | Heinrich-Heine-Universität Düsseldorf | Agonistes du récepteur a2a phosphorylé |
| MX361102B (es) | 2013-12-19 | 2018-11-27 | Procter & Gamble | Modelado de fibras de queratina con el uso de un agente activo que comprende al menos dos grupos funcionales seleccionados de: -c(oh)- y -c(=o)oh. |
| MX2017008204A (es) | 2014-12-19 | 2017-10-06 | Procter & Gamble | Conformacion de las fibras de queratina mediante el uso de arabinosa y carbonato de etileno. |
| EP3297730A1 (fr) | 2014-12-19 | 2018-03-28 | The Procter and Gamble Company | Procédé de mise en forme de fibres de kératine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3796700A (en) * | 1970-06-30 | 1974-03-12 | Takedo Chem Ind Ltd | Adenosine derivatives and the production thereof |
| JPH0696534B2 (ja) * | 1986-04-25 | 1994-11-30 | ヘキストジヤパン株式会社 | 抗痴呆剤 |
| US5017578A (en) * | 1989-06-09 | 1991-05-21 | Hoechst-Roussel Pharmaceuticals Inc. | N-heteroaryl-purin-6-amines useful as analgesic and anticonvulsant agents |
| PT95628A (pt) * | 1989-10-19 | 1991-09-30 | Searle & Co | Metodo de tratamento de perturbacoes de mobilidade gastrointestinal com composto de adenosina |
| US5432164A (en) * | 1991-10-24 | 1995-07-11 | Novo Nordisk A/S | C2,N6 -disubstituted adenosine derivatives |
-
1992
- 1992-10-20 US US07/963,878 patent/US5432164A/en not_active Expired - Fee Related
- 1992-10-21 JP JP5507362A patent/JPH07500586A/ja active Pending
- 1992-10-21 AU AU29160/92A patent/AU657374B2/en not_active Ceased
- 1992-10-21 WO PCT/DK1992/000307 patent/WO1993008206A1/fr not_active Application Discontinuation
- 1992-10-21 EP EP92923113A patent/EP0609375A1/fr not_active Ceased
- 1992-10-21 CA CA002121844A patent/CA2121844A1/fr not_active Abandoned
- 1992-10-22 IL IL10351392A patent/IL103513A/en not_active IP Right Cessation
- 1992-10-23 NZ NZ244875A patent/NZ244875A/en unknown
- 1992-10-23 ZA ZA928222A patent/ZA928222B/xx unknown
-
1994
- 1994-04-22 NO NO941477A patent/NO300461B1/no unknown
- 1994-04-22 FI FI941876A patent/FI941876A/fi not_active Application Discontinuation
-
1995
- 1995-05-05 US US08/435,005 patent/US5578582A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US5432164A (en) | 1995-07-11 |
| IL103513A0 (en) | 1993-03-15 |
| CA2121844A1 (fr) | 1993-04-29 |
| NZ244875A (en) | 1995-04-27 |
| WO1993008206A1 (fr) | 1993-04-29 |
| NO941477D0 (no) | 1994-04-22 |
| AU2916092A (en) | 1993-05-21 |
| FI941876A (fi) | 1994-06-22 |
| JPH07500586A (ja) | 1995-01-19 |
| EP0609375A1 (fr) | 1994-08-10 |
| AU657374B2 (en) | 1995-03-09 |
| US5578582A (en) | 1996-11-26 |
| FI941876A0 (fi) | 1994-04-22 |
| IL103513A (en) | 1996-09-12 |
| NO941477L (fr) | 1994-06-23 |
| ZA928222B (en) | 1994-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5589467A (en) | 2,5',N6-trisubstituted adenosine derivatives | |
| NO300461B1 (no) | 2,6-Disubstituerte purinderivater | |
| US6455510B1 (en) | Chemical Compounds | |
| EP1252160B1 (fr) | Analogues nucleosidiques de methanocarba cycloalkyle | |
| AU2001230913A1 (en) | Methanocarba cycloalkyl nucleoside analogues | |
| US6753322B2 (en) | 2-aminocarbonyl-9H-purine derivatives | |
| CA2945693A1 (fr) | Derives de nucleosides a substitution 4'-difluoromethyle utilises en tant qu'inhibiteurs de la replication de l'arn du virus de la grippe | |
| US5430027A (en) | 2-chloro-N6 -substituted adenosines, their pharmaceutical compositions, and activity in treating ischemias | |
| KR100585894B1 (ko) | Ｃ2,5'-이치환된 및 ｎ6,ｃ2,5'-삼치환된 아데노신 유도체및 그들의 상이한 용도 | |
| WO2000023447A1 (fr) | Analogues de l'adenosine presentant des proprietes anti-hypertensives, cardioprotectrices, anti-ischemiques et antilipolytiques | |
| US5484774A (en) | 2, N6 -disubstituted adenosines, tri-O-ester derivatives and their pharmaceutical compositions to treat ischemias | |
| US5683989A (en) | Treatment of ischemias by administration of 2,N6 -substituted adenosines | |
| WO1998016539A1 (fr) | Nouveaux derives d'adenosine a action therapeutique | |
| WO1997033591A1 (fr) | Procede de traitement d'affections associees aux cytokines chez les mammiferes | |
| CN110381955A (zh) | 用于预防及治疗青光眼的含有腺苷衍生物的药物组合物 | |
| WO1997033590A1 (fr) | Procede de traitement d'affections associees aux cytokines chez les mammiferes | |
| Knutsen et al. | C2, N 6-disubstituted adenosine derivatives | |
| US5672588A (en) | Purine derivatives |